Back to Search Start Over

Statin safety and associated adverse events: a scientific statement from the American Heart Association

Authors :
P. Barton Duell
Lynne T. Braun
Jonathan A. Tobert
Larry B. Goldstein
Lisa R. Tannock
Michael Miller
Eliot A. Brinton
Francine K. Welty
Clifford Chin
Connie B. Newman
Geetha Raghuveer
Vascular Biology
Amy Pollak
Robert L. Page
David Preiss
Terry A. Jacobson
Publication Year :
2019
Publisher :
American Heart Association, 2019.

Abstract

One in 4 Americans >40 years of age takes a statin to reduce the risk of myocardial infarction, ischemic stroke, and other complications of atherosclerotic disease. The most effective statins produce a mean reduction in low-density lipoprotein cholesterol of 55% to 60% at the maximum dosage, and 6 of the 7 marketed statins are available in generic form, which makes them affordable for most patients. Primarily using data from randomized controlled trials, supplemented with observational data where necessary, this scientific statement provides a comprehensive review of statin safety and tolerability. The review covers the general patient population, as well as demographic subgroups, including the elderly, children, pregnant women, East Asians, and patients with specific conditions such as chronic disease of the kidney and liver, human immunodeficiency viral infection, and organ transplants. The risk of statin-induced serious muscle injury, including rhabdomyolysis, is

Details

Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....ae3e3feb0b8d9b97d04b0388ee0fcc85